Michael Rosu-Myles
Overview
Explore the profile of Michael Rosu-Myles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
781
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
de la Guardia R, Lopez-Millan B, Roca-Ho H, Bueno C, Gutierrez-Aguera F, Fuster J, et al.
Haematologica
. 2018 Sep;
104(2):e54-e58.
PMID: 30237260
No abstract available.
22.
Barrera-Ramirez J, Lavoie J, Maganti H, Stanford W, Ito C, Sabloff M, et al.
Stem Cell Rev Rep
. 2017 Sep;
13(6):817-825.
PMID: 28918518
Gene regulatory networks in AML may be influenced by microRNAs (miRs) contained in exosomes derived from bone marrow mesenchymal stromal cells (MSCs). We sequenced miRs from exosomes isolated from marrow-derived...
23.
de la Guardia R, Lopez-Millan B, Lavoie J, Bueno C, Castano J, Gomez-Casares M, et al.
Stem Cell Reports
. 2017 May;
8(6):1573-1586.
PMID: 28528702
Bone marrow mesenchymal stem/stromal cells (BM-MSCs) are key components of the hematopoietic niche thought to have a direct role in leukemia pathogenesis. BM-MSCs from patients with acute myeloid leukemia (AML)...
24.
Lopez-Millan B, de la Guardia R, Roca-Ho H, Garcia-Herrero C, Lavoie J, Rosu-Myles M, et al.
Exp Mol Med
. 2017 Feb;
49(2):e290.
PMID: 28154372
Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide...
25.
Lavoie J, Creskey M, Muradia G, Bell G, Sherman S, Gao J, et al.
Stem Cells
. 2016 Apr;
34(8):2249-55.
PMID: 27090767
Multipotent mesenchymal stromal cell (MSC) transplantation is proposed as a novel therapy for treating diabetes by promoting the regeneration of damaged islets. The clinical promise of such treatments may be...
26.
Le Y, Fraineau S, Chandran P, Sabloff M, Brand M, Lavoie J, et al.
Stem Cell Rev Rep
. 2015 Dec;
12(2):235-44.
PMID: 26649729
Purpose: The role of bone marrow-derived mesenchymal stem/stromal cells (MSCs) in creating a permissive microenvironment that supports the emergence and progression of acute myeloid leukemia (AML) is not well established....
27.
Ridgway A, Agbanyo F, Wang J, Rosu-Myles M
Adv Exp Med Biol
. 2015 Sep;
871:49-71.
PMID: 26374212
Health Canada regulates gene therapy products and many cell therapy products as biological drugs under the Canadian Food and Drugs Act and its attendant regulations. Cellular products that meet certain...
28.
Cook M, Kaldas S, Muradia G, Rosu-Myles M, Kunkel J
J Chromatogr B Analyt Technol Biomed Life Sci
. 2015 Jun;
997:162-78.
PMID: 26114652
The N-linked glycosylation of four lots of a marketed human therapeutic monoclonal antibody (mAb) was assessed by three orthogonal chromatographic methods and a commercial lectin microarray. For chromatography, the N-glycans...
29.
Chandran P, Le Y, Li Y, Sabloff M, Mehic J, Rosu-Myles M, et al.
Leuk Res
. 2015 Feb;
39(4):486-93.
PMID: 25703353
The bone marrow microenvironment may be permissive to the emergence and progression of acute myeloid leukemia (AML). Studying interactions between the microenvironment and leukemia cells should provide new insight for...
30.
Rodriguez R, Rosu-Myles M, Arauzo-Bravo M, Horrillo A, Pan Q, Gonzalez-Rey E, et al.
Stem Cell Reports
. 2014 Nov;
3(4):606-19.
PMID: 25358789
Because of their immunomodulatory properties, human bone marrow stromal cells (hBMSCs) represent promising stem cells for treatment of immune disorders. hBMSCs expansion precedes their clinical use, so the possibility that...